Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | UGCG | Q16739 | 2/20 | 0.40 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25308726 | 1.00 | LMNA (0.48) | LMNAHRH4HRH3TAAR1SLC6A2 | |
| SCHEMBL1566074 | 1.00 | LMNA (0.48) | LMNAHRH4HRH3TAAR1SLC6A2 | |
| SCHEMBL25309758 | 1.00 | LMNA (0.48) | LMNAHRH4HRH3TAAR1SLC6A2 | |
| SCHEMBL25308921 | 0.88 | LMNA (0.48) | LMNAHRH4HRH3TAAR1SLC6A2 | |
| SCHEMBL18636612 | 0.88 | LMNA (0.48) | LMNAHRH4HRH3TAAR1SLC6A2 | |
| SCHEMBL19559233 | 0.85 | LMNA (0.54) | LMNAHRH4HRH3TAAR1TSHR | |
| SCHEMBL10420228 | 0.85 | LMNA (0.54) | LMNAHRH4HRH3TAAR1TSHR | |
| SCHEMBL29295667 | 0.85 | LMNA (0.47) | LMNAHRH4HRH3TAAR1SLC6A2 | |
| SCHEMBL30063100 | 0.83 | TAAR1 (0.47) | LMNAHRH4HRH3TAAR1SLC6A2 | |
| SCHEMBL18650433 | 0.83 | LMNA (0.47) | LMNAHRH4HRH3TAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516046-B2 | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-11802122-B2 | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230312528-A1 | 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230227441-A1 | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-20 | — | — | US | disclosed |
| CN-116134018-A | 2-oxoimidazolidine-4-carboxamide as NAV1.8 inhibitor | 默沙东有限责任公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-116056697-A | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors | 默沙东有限责任公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-4167994-A1 | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4168393-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20210403457-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-30 | — | — | US | disclosed |
| WO-2021257490-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | WO | disclosed |
| US-9023839-B2 | Compounds and compositions as c-kit kinase inhibitors | IRM LLC (BM) | 2015-05-05 | — | — | US | disclosed |
| US-20140228347-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-08-14 | — | — | US | disclosed |
| EP-2751104-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-07-09 | — | — | EP | disclosed |
| US-8754071-B2 | Compounds and compositions as c-kit kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-06-17 | — | — | US | disclosed |
| US-20140031333-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-01-30 | — | — | US | disclosed |
| US-8569283-B2 | Compounds and compositions as c-Kit kinase inhibitors | IRM LLC (BM) | 2013-10-29 | — | — | US | disclosed |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | disclosed |
| WO-2013033167-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403457-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | LMNA 3683/4885HRH4 170/4885HRH3 438/4885 |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | CCND3, CDK3, CDK2 | LMNA 574/4885HRH4 3492/4885HRH3 1849/4885 |
| US-20140031333-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | LMNA 900/4885HRH4 3623/4885HRH3 2306/4885 |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | LMNA 900/4885HRH4 3623/4885HRH3 2306/4885 |
| US-20140228347-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | LMNA 900/4885HRH4 3623/4885HRH3 2306/4885 |
| US-20230227441-A1 | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | LMNA 3554/4885HRH4 264/4885HRH3 674/4885 |
| US-11802122-B2 | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors | SCN8A, TRPV1, SCN2A | LMNA 3683/4885HRH4 170/4885HRH3 438/4885 |
| US-20230312528-A1 | 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | LMNA 3647/4885HRH4 183/4885HRH3 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.